STOCK TITAN

Perrigo Co Plc - PRGO STOCK NEWS

Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.

Overview

Perrigo Company Plc (PRGO) is a foremost global provider of over-the-counter consumer self-care products and affordable health solutions. With roots dating back to 1887, the company has evolved from packaging generic home remedies to a focused, pure-play consumer self-care business, specializing in a wide range of products from infant formulas to branded over-the-counter healthcare solutions.

Core Business and Product Portfolio

Perrigo operates across a spectrum of product categories that include store brand offerings and nationally recognized branded products. Its portfolio covers key segments such as infant formula for store brands, branded OTC products, and innovative health solutions like its pioneering over-the-counter daily birth control pill. With a robust blend of store brand and national brands, Perrigo’s business model is anchored on providing quality, accessible healthcare options that empower individuals to manage minor health conditions effectively.

Market Position and Global Presence

Positioned as one of the largest consumer health companies, Perrigo’s operations extend primarily across North America, Europe, Australia, and strategic markets in Asia and the Middle East. Its extensive distribution network includes major retailers such as Walmart, Amazon, Costco, and CVS, underscoring a resilient and expansive market reach. The company’s commitment to 'quality affordable healthcare products' is reflected in its tailored approach to meet diverse consumer needs, offering products that blend trusted efficacy with competitive pricing.

Business Model and Strategic Initiatives

Perrigo’s revenue is driven by a well-diversified product mix that leverages both private-label and branded offerings. Its transformation into a pure-play consumer self-care company was achieved through strategic divestments in areas such as animal health and generic pharmaceuticals, allowing a sharper focus on consumer self-care. The integrated business model maximizes profitability by reinvesting savings through operational efficiency programs and strengthening high-growth segments. Initiatives aimed at innovation and operational streamlining, such as the globally recognized Project Energize, underscore its commitment to maintaining competitive cost structures and enhancing product margins.

Innovation and Consumer-Focused Strategy

Innovation remains a cornerstone of Perrigo’s strategy. The company continuously invests in new product launches and refinements that align with evolving consumer needs and regulatory changes. Its recent advancements in the reproductive health space—exemplified by partnerships that enhance health education and access—demonstrate a commitment to addressing critical areas of consumer well-being. Such initiatives not only reinforce brand strength but also contribute to market differentiation within the competitive landscape of OTC health and wellness solutions.

Industry Expertise and Differentiation

Perrigo’s long-established presence and expertise in the consumer health arena are backed by decades of operational excellence and strategic leadership. The company’s ability to consistently deliver high-quality, affordable products positions it uniquely among its peers. Detailed management succession plans and operational transitions further exemplify its robust internal expertise and focus on sustaining long-term value creation. By harnessing a blended-branded approach, Perrigo successfully addresses various consumer demographics, ensuring accessibility to essential health products across multiple price points.

Conclusion

Overall, Perrigo Company Plc remains an influential force in the global consumer self-care market. Its commitment to quality, affordability, and continuous innovation serves as a testament to its proven business model. For investors and market analysts alike, Perrigo offers a comprehensive case study in achieving market resilience and operational excellence in a rapidly evolving healthcare landscape.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
Rhea-AI Summary
Perrigo Company plc announced that Murray S. Kessler will retire as President and CEO, effective July 31, 2023. Kessler led the transformation of Perrigo into a consumer self-care company, eliminating a $4 billion tax and legal overhang. Perrigo is growing its top line, margins, and bottom line, with a plan to reduce leverage and deliver strong growth. The Board is actively working on succession planning to find a new CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
dividends
-
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) announced plans to release its first quarter 2023 financial results on May 9, 2023, accompanied by a conference call at 8:30 A.M. (EST). The conference call will be accessible via live webcast on Perrigo's investor relations website. A taped replay will be available from 12:00 P.M. (EST) on May 9 until midnight on May 16, 2023.

Perrigo focuses on Consumer Self-Care Products and over-the-counter health solutions, aiming to empower consumers in managing their health independently. The company warns that the earnings report may include forward-looking statements, which are subject to various risks and uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
-
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) announced a rescheduled FDA meeting set for May 9-10, 2023, to review their application for the Opill® daily oral contraceptive for over-the-counter (OTC) availability. If approved, Opill® would be the first OTC daily birth control pill in the U.S. This initiative is supported by key medical organizations advocating for increased access to contraception. The establishment of a dedicated Women's Health strategic organization reflects Perrigo's commitment to addressing women's health needs, aiming to empower individuals with affordable contraceptive options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) announced that its President and CEO, Murray S. Kessler, along with CFO Eduardo Bezerra, will present at the 12th Annual UBS Global Consumer and Retail Conference on March 15, 2023, at 3:00 PM EST in New York City. The presentation aims to discuss their consumer self-care products and OTC health solutions.

Interested parties can access the live presentation via the Perrigo website at http://perrigo.investorroom.com/events-webcasts. For more information on the company, visit www.perrigo.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
conferences
Rhea-AI Summary

Perrigo Company plc (NYSE: PRGO) announced FDA approval for its Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, an over-the-counter equivalent to Advil Dual Action Tablets. This approval, received on the first day after Advil's marketing exclusivity expiration, showcases Perrigo's regulatory competency. The company plans to launch the product in Spring 2023. Retail sales for the national brand reached approximately $69 million in the past year. This dual-action formulation is designed to relieve various pain symptoms, reinforcing Perrigo's position in the consumer health market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags

FAQ

What is the current stock price of Perrigo Co Plc (PRGO)?

The current stock price of Perrigo Co Plc (PRGO) is $26.9 as of April 3, 2025.

What is the market cap of Perrigo Co Plc (PRGO)?

The market cap of Perrigo Co Plc (PRGO) is approximately 3.7B.

What products does Perrigo offer?

Perrigo offers a diverse range of over-the-counter self-care products including infant formulas, branded healthcare items, and store-brand OTC products designed to address everyday health needs.

How has Perrigo evolved over the years?

Founded in 1887 as a provider of generic home remedies, Perrigo has transformed into a specialized consumer self-care company focusing on high-quality, affordable OTC health solutions.

What is Perrigo's core business model?

Perrigo’s business model centers on a blend of private-label and national brand products, leveraging operational efficiencies and strategic divestments to concentrate on consumer self-care and OTC health solutions.

Which markets are key to Perrigo's global presence?

Perrigo primarily operates in North America, Europe, and Australia, with additional strategic markets in Asia and other regions, supported by a robust distribution network with major retailers.

How does Perrigo differentiate itself from competitors?

The company differentiates itself through its long-standing focus on affordability, high-quality products, and continuous innovation, coupled with operational efficiency programs and a diversified product mix.

What recent innovations has Perrigo introduced?

Recent innovations include breakthrough products such as the first over-the-counter daily birth control pill, which reflect Perrigo’s commitment to consumer health education and accessibility.

How does Perrigo maintain its commitment to affordable healthcare?

Perrigo reinforces affordability by streamlining its operations, focusing on high-volume store-brand products, and reinvesting cost-saving initiatives into developing and enhancing consumer self-care solutions.

What strategic initiatives support Perrigo's business transformation?

Key initiatives such as Project Energize are instrumental in driving operational efficiencies and margin expansion, supporting the company’s strategic transformation into a pure-play consumer self-care leader.
Perrigo Co Plc

NYSE:PRGO

PRGO Rankings

PRGO Stock Data

3.73B
135.94M
0.34%
101.68%
3.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2